In Re Namenda Direct Purchaser Antitrust Litigation

  1. June 21, 2017

    Forest Denied Drug Wholesalers' Profit Docs In Namenda Suit

    A federal magistrate judge on Wednesday shot down a bid by Forest Laboratories LLC to obtain profit information from a proposed class of drug wholesalers accusing the company of restricting competition by blocking generic versions of Alzheimer's drug Namenda, saying it is not clear how the information is relevant.

  2. June 16, 2017

    Forest Says Namenda Buyers Can't Use Its Own Consultant

    Forest Laboratories LLC on Thursday asked a New York federal court to disqualify Namenda buyers' expert witness, as he consulted with the drug company for nearly 15 years, including on the patent litigation at the heart of this pay-for-delay proposed class action.

  3. May 25, 2017

    Drug Wholesalers Blast Forest's Bid For Profit Docs

    A proposed class of drug wholesalers urged a New York federal judge Wednesday to deny Forest Laboratories LLC's request for certain documents in an antitrust suit alleging the drugmaker blocked generics for its Namenda Alzheimer's treatment, saying their profit information is irrelevant in an antitrust case.

  4. May 04, 2017

    Forest Blasts Bid For Namenda Patent Litigation Docs

    Forest Laboratories LLC on Wednesday shot back against a proposed class of drug wholesalers' attempt to get certain documents in an antitrust suit alleging the drugmaker blocked generic versions of its Alzheimer's drug Namenda, saying the motion in New York federal court was "premature."

  5. April 13, 2017

    Purchasers Seek Namenda Litigation Docs In Antitrust Suit

    A proposed class of drug wholesalers accusing an Allergan PLC unit of antitrust violations asked a New York federal judge on Wednesday to force production of documents relating to the drugmaker's alleged attempts to prevent competition from generic versions of the Alzheimer's treatment Namenda.

  6. March 22, 2017

    Drug Cos. Fight Bid For Quick Win In Namenda Antitrust Suit

    An Allergan PLC unit asked a New York federal judge to deny drug wholesalers' bid for a win on a federal antitrust claim in their lawsuit over the Alzheimer's treatment Namenda, arguing Tuesday that findings from a previously litigated case have nothing to do with the matter at hand. 

  7. March 17, 2017

    Allergan Defends 3-Month Exclusivity Deal For Namenda

    Pharmaceutical patent holders that sue generic-drug manufacturers for infringement and then shorten product exclusivity periods via settlements shouldn't have to actually win those cases to maintain exclusivity, an Allergan unit told a New York federal judge Friday in a lawsuit over Alzheimer's treatment Namenda.

  8. February 02, 2016

    Namenda Buyers Say Product Hopping Class Action Has Legs

    Drug wholesalers accusing Actavis and Merz of trying to stall the release of a generic version of the Alzheimer's treatment Namenda urged a New York federal judge Friday not to toss the their putative class action, saying their complaint sufficiently alleges that the companies violated antitrust laws.

  9. December 23, 2015

    Actavis Says Namenda Product-Hopping Suit Has No Hop

    Pharmaceutical companies Actavis and Merz told a New York federal court Tuesday they cannot be sued for "product hopping" the Alzheimer's treatment Namenda, because the drug's original version was never pulled off the market and a generic has since been released.